AU2004228929B2 - Organic compounds - Google Patents

Organic compounds Download PDF

Info

Publication number
AU2004228929B2
AU2004228929B2 AU2004228929A AU2004228929A AU2004228929B2 AU 2004228929 B2 AU2004228929 B2 AU 2004228929B2 AU 2004228929 A AU2004228929 A AU 2004228929A AU 2004228929 A AU2004228929 A AU 2004228929A AU 2004228929 B2 AU2004228929 B2 AU 2004228929B2
Authority
AU
Australia
Prior art keywords
alkyl
composition according
halogen
substituted
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired, expires
Application number
AU2004228929A
Other languages
English (en)
Other versions
AU2004228929A1 (en
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Alan Edward Royce
Colleen Ruegger
Masaki Sasaki
Tokuhiro Tamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Tanabe Pharma Corp
Original Assignee
Novartis AG
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004228929(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, Mitsubishi Tanabe Pharma Corp filed Critical Novartis AG
Publication of AU2004228929A1 publication Critical patent/AU2004228929A1/en
Priority to AU2008200368A priority Critical patent/AU2008200368B2/en
Application granted granted Critical
Publication of AU2004228929B2 publication Critical patent/AU2004228929B2/en
Assigned to MITSUBISHI TANABE PHARMA CORPORATION, NOVARTIS AG reassignment MITSUBISHI TANABE PHARMA CORPORATION Request to Amend Deed and Register Assignors: MITSUBISHI PHARMA CORPORATION, NOVARTIS AG
Adjusted expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2004228929A 2003-04-08 2004-04-06 Organic compounds Expired AU2004228929B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008200368A AU2008200368B2 (en) 2003-04-08 2008-01-24 Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08
US60/461,215 2003-04-08
PCT/EP2004/003656 WO2004089341A1 (en) 2003-04-08 2004-04-06 Organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008200368A Division AU2008200368B2 (en) 2003-04-08 2008-01-24 Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol

Publications (2)

Publication Number Publication Date
AU2004228929A1 AU2004228929A1 (en) 2004-10-21
AU2004228929B2 true AU2004228929B2 (en) 2008-02-07

Family

ID=32326722

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004228929A Expired AU2004228929B2 (en) 2003-04-08 2004-04-06 Organic compounds

Country Status (41)

Country Link
US (11) US20060275357A1 (cg-RX-API-DMAC10.html)
EP (5) EP2319502A1 (cg-RX-API-DMAC10.html)
JP (3) JP5495467B2 (cg-RX-API-DMAC10.html)
KR (3) KR20110005320A (cg-RX-API-DMAC10.html)
CN (2) CN101797241B (cg-RX-API-DMAC10.html)
AR (3) AR043987A1 (cg-RX-API-DMAC10.html)
AT (3) AT501681B1 (cg-RX-API-DMAC10.html)
AU (1) AU2004228929B2 (cg-RX-API-DMAC10.html)
BE (2) BE1015972A5 (cg-RX-API-DMAC10.html)
BR (1) BRPI0409250B8 (cg-RX-API-DMAC10.html)
CA (2) CA2521325C (cg-RX-API-DMAC10.html)
CL (2) CL2004000745A1 (cg-RX-API-DMAC10.html)
CY (3) CY1110260T1 (cg-RX-API-DMAC10.html)
DE (4) DE202004021680U1 (cg-RX-API-DMAC10.html)
DK (2) DK1613288T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP056090A (cg-RX-API-DMAC10.html)
ES (3) ES2228282B1 (cg-RX-API-DMAC10.html)
FR (2) FR2854073B1 (cg-RX-API-DMAC10.html)
GB (1) GB2400318B (cg-RX-API-DMAC10.html)
GR (1) GR1005052B (cg-RX-API-DMAC10.html)
HR (3) HRP20100601B1 (cg-RX-API-DMAC10.html)
HU (2) HUE028247T2 (cg-RX-API-DMAC10.html)
IL (3) IL170888A (cg-RX-API-DMAC10.html)
IS (2) IS2682B (cg-RX-API-DMAC10.html)
IT (1) ITMI20040682A1 (cg-RX-API-DMAC10.html)
LU (1) LU91867I2 (cg-RX-API-DMAC10.html)
MA (1) MA27729A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA05010860A (cg-RX-API-DMAC10.html)
MY (1) MY141249A (cg-RX-API-DMAC10.html)
NO (4) NO329332B1 (cg-RX-API-DMAC10.html)
NZ (3) NZ542622A (cg-RX-API-DMAC10.html)
PE (5) PE20150676A1 (cg-RX-API-DMAC10.html)
PL (2) PL2316431T3 (cg-RX-API-DMAC10.html)
PT (1) PT1613288E (cg-RX-API-DMAC10.html)
RU (5) RU2358716C2 (cg-RX-API-DMAC10.html)
SG (1) SG175449A1 (cg-RX-API-DMAC10.html)
SI (2) SI2316431T1 (cg-RX-API-DMAC10.html)
TN (1) TNSN05256A1 (cg-RX-API-DMAC10.html)
TW (1) TWI332847B (cg-RX-API-DMAC10.html)
WO (1) WO2004089341A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200507394B (cg-RX-API-DMAC10.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096972A1 (en) * 2004-07-30 2008-04-24 Thitiwan Buranachokpaisan Compound formulations of 2-amino-1, 3-propanediol compounds
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
PT2295049E (pt) * 2005-09-09 2015-03-02 Novartis Ag Tratamento de doenças auto-imunes
MX2008006090A (es) 2005-11-09 2008-10-23 Proteolix Inc Compuestos para inhibicion de la enzima.
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
RU2450016C2 (ru) 2006-06-19 2012-05-10 Протеоликс, Инк. Пептидные эпоксикетоны для ингибирования протеасомы
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
KR101884047B1 (ko) * 2006-09-26 2018-07-31 노파르티스 아게 Ｓ１ｐ 조정제를 포함하는 제약 조성물
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
CN104324015B (zh) 2007-03-29 2018-08-28 第一三共株式会社 药物组合物
KR20160086980A (ko) 2007-10-04 2016-07-20 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
PL2465492T3 (pl) 2007-10-12 2015-11-30 Novartis Ag Mieszaniny zawierające modulatory receptora 1-fosforanu sfingozyny (S1P)
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
WO2009099174A1 (ja) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
HRP20170246T4 (hr) 2008-03-17 2020-02-07 Actelion Pharmaceuticals Ltd. Režim doziranja za selektivni agonist s1p1-receptora
MX2010014223A (es) 2008-06-20 2011-01-21 Novartis Ag Composiciones pediatricas para el tratamiento de esclerosis multiple.
EP2299982B1 (de) * 2008-06-20 2018-04-04 Merck Patent GmbH Direkt verpressbare und schnell zerfallende tablettenmatirx
RU2498636C2 (ru) * 2008-09-04 2013-11-20 Карджилл Инкорпорейтед Таблетирование эритрита
MX2011004225A (es) 2008-10-21 2011-06-21 Onyx Therapeutics Inc Terapia de combinacion con epoxicetonas peptidicas.
AU2009315735B2 (en) 2008-11-11 2013-01-10 Novartis Ag Salts of fingolimod
US8530522B2 (en) * 2008-11-11 2013-09-10 Novartis Ag Organic compounds
AU2013100532B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
CA2747427C (en) 2008-12-17 2015-10-13 Daiichi Sankyo Company, Limited Method for producing diamine derivative
JPWO2010082531A1 (ja) 2009-01-13 2012-07-05 第一三共株式会社 活性化血液凝固因子阻害剤
CN102348688B (zh) 2009-03-10 2014-07-09 第一三共株式会社 用于制备二胺衍生物的方法
EP2407450B1 (en) 2009-03-13 2015-04-22 Daiichi Sankyo Company, Limited Method for producing optically active diamine derivative
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
SG176934A1 (en) * 2009-06-18 2012-01-30 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved solubility
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
BR112012022060A2 (pt) 2010-03-01 2018-05-08 Onyx Therapeutics Inc composto para a inibição de imunoproteassoma
EP2548556B1 (en) 2010-03-19 2016-08-10 Daiichi Sankyo Company, Limited Method for improving dissolvability of anticoagulant
ES2560955T3 (es) 2010-03-19 2016-02-23 Daiichi Sankyo Company, Limited Cristal de derivado de diamina y procedimiento de producción del mismo
US20130095177A1 (en) * 2010-04-22 2013-04-18 Ratiopharm Gmbh Method of preparing an oral dosage form comprising fingolimod
KR101795096B1 (ko) 2010-07-02 2017-12-01 다이이찌 산쿄 가부시키가이샤 광학 활성 디아민 유도체의 염의 제조 방법
EP2646409A4 (en) 2010-11-25 2015-12-16 Shilpa Medicare Ltd FINGOLIMOD POLYMORPHES AND METHOD THEREFOR
HRP20191842T1 (hr) 2011-01-07 2019-12-27 Novartis Ag Formulacije imunosupresiva
US8858991B2 (en) 2011-01-19 2014-10-14 Pathologica Llc Delayed release oral pharmaceutical dosage forms comprising MGBG
AR085749A1 (es) * 2011-04-01 2013-10-23 Novartis Ag Formulaciones
EA028950B1 (ru) 2011-08-01 2018-01-31 Тева Фармасьютикал Индастриз Лтд. Способ получения фармацевтических композиций, содержащих финголимод
JPWO2013022059A1 (ja) 2011-08-10 2015-03-05 第一三共株式会社 ジアミン誘導体含有医薬組成物
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
EP3831372A1 (en) 2013-01-08 2021-06-09 Pathologica LLC Mitoguazone for preventing the relapse or the progression of multiple sclerosis
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
US9629834B2 (en) * 2013-04-26 2017-04-25 Kyoto University Medicinal composition for inhibiting formation and/or enlargement of cerebral aneurysm or shrinking same
WO2013190151A1 (en) * 2013-05-13 2013-12-27 Synthon B.V. Pharmaceutical composition comprising fingolimod
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CN107530301A (zh) * 2015-01-20 2018-01-02 汉达医药有限责任公司 稳定的固体芬戈莫德剂型
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
EP4181906A1 (en) 2020-07-16 2023-05-24 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
JP2024506825A (ja) * 2021-01-28 2024-02-15 プリオセラ エスエーエス Ｓ１ｐ受容体調節剤による処置の方法
AU2021424131A1 (en) * 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002792A1 (en) * 1997-04-04 2000-05-24 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
JP2579602B2 (ja) 1992-10-21 1997-02-05 吉富製薬株式会社 ２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤
WO1996006068A1 (en) 1994-08-22 1996-02-29 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and medicinal use thereof
DE69633613T2 (de) 1995-12-28 2006-02-09 Mitsubishi Pharma Corp. 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-diol enthaltendes Arzneimittel zur topischen Anwendung zur Behandlung von Erkrankungen,die durch eine Störung des Immunsystems hervorgerufen werden
JPH11209277A (ja) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
PT990440E (pt) * 1997-02-27 2009-02-05 Novartis Ag Composição farmacêutica compreendendo 2-amino-2-[2-(4-octilfenil)etil]propano-1,3-diol, uma lecitina e um sacárido
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
EP1195165A4 (en) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
AU2001269503B2 (en) 2000-07-13 2005-02-17 Sankyo Company, Limited Amino alcohol derivatives
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
MXPA03008755A (es) 2001-03-26 2004-02-18 Novartis Ag Derivados de 2-amino-propanol.
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20040235794A1 (en) 2001-09-04 2004-11-25 Shinji Nakade Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
CA2460640C (en) 2001-09-27 2011-03-29 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same
AU2002332289B2 (en) 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
AU2003216054B2 (en) 2002-01-18 2007-01-04 Merck & Co., Inc. Selective S1P1/Edg1 receptor agonists
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
WO2003062248A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
MX2007000564A (es) * 2004-07-16 2007-03-30 Kyorin Seiyaku Kk Metodo para utilizar efectivamente medicamentos referentes a la prevencion de efectos secundarios.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002792A1 (en) * 1997-04-04 2000-05-24 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents

Also Published As

Publication number Publication date
MA27729A1 (fr) 2006-01-02
SG175449A1 (en) 2011-11-28
US20090203798A1 (en) 2009-08-13
GR20040100121A (el) 2004-12-17
MXPA05010860A (es) 2006-05-25
PE20050396A1 (es) 2005-07-05
TWI332847B (en) 2010-11-11
CN1767819A (zh) 2006-05-03
ES2228282B1 (es) 2006-02-16
ES2556947T3 (es) 2016-01-21
AT501681B1 (de) 2012-04-15
TNSN05256A1 (en) 2007-07-10
JP2011006461A (ja) 2011-01-13
JP2013177404A (ja) 2013-09-09
JP2004307506A (ja) 2004-11-04
AU2004228929A1 (en) 2004-10-21
LU91867I2 (fr) 2011-11-08
EP1613288B1 (en) 2008-11-19
RU2010146697A (ru) 2012-05-27
GR1005052B (el) 2005-11-30
GB2400318A (en) 2004-10-13
EP2008650A3 (en) 2011-04-27
HRP20050886B1 (en) 2011-01-31
IS8885A (is) 2010-02-25
GB0407819D0 (en) 2004-05-12
BRPI0409250B8 (pt) 2022-01-18
CN101797241B (zh) 2013-03-27
CY1117071T1 (el) 2017-04-05
CA2707750A1 (en) 2004-10-21
LU91867I9 (cg-RX-API-DMAC10.html) 2019-01-03
SI1613288T1 (sl) 2009-04-30
US20130108675A1 (en) 2013-05-02
EP1613288A1 (en) 2006-01-11
NO329332B1 (no) 2010-09-27
PE20131352A1 (es) 2013-11-14
KR20110005320A (ko) 2011-01-17
BRPI0409250A (pt) 2006-03-28
RU2358716C2 (ru) 2009-06-20
ES2320767T3 (es) 2009-05-28
IL170888A (en) 2010-06-16
CN1767819B (zh) 2010-07-28
US20140011885A1 (en) 2014-01-09
KR20050121712A (ko) 2005-12-27
PE20150676A1 (es) 2015-05-17
NO2011016I1 (no) 2011-09-19
EP2319502A1 (en) 2011-05-11
GB2400318B (en) 2005-08-10
PE20130200A1 (es) 2013-03-09
NO20131287L (no) 2006-01-09
PE20090743A1 (es) 2009-07-17
RU2475237C2 (ru) 2013-02-20
DK2316431T3 (en) 2016-01-11
NZ592339A (en) 2012-09-28
WO2004089341A1 (en) 2004-10-21
CY1110260T1 (el) 2014-04-09
ECSP056090A (es) 2006-03-01
RU2475236C2 (ru) 2013-02-20
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
AR078781A2 (es) 2011-11-30
SI2316431T1 (sl) 2016-04-29
AT504853A2 (de) 2008-08-15
IE20040246A1 (en) 2004-12-15
DK1613288T3 (da) 2009-03-23
NZ586280A (en) 2011-12-22
US20220031609A1 (en) 2022-02-03
DE122011100047I1 (de) 2011-12-15
DE202004021680U1 (de) 2010-04-22
CA2521325C (en) 2010-09-14
ES2228282A1 (es) 2005-04-01
IS2682B (is) 2010-10-15
NO2011016I2 (no) 2012-08-27
US20140255497A1 (en) 2014-09-11
HUS1100016I1 (hu) 2016-08-29
IL242037A0 (en) 2015-11-30
IS8114A (is) 2005-11-01
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
EP2316431B1 (en) 2015-09-30
NO20055231D0 (no) 2005-11-07
US20170290787A1 (en) 2017-10-12
CY2011013I2 (el) 2014-04-09
BE2011C030I2 (cg-RX-API-DMAC10.html) 2023-03-07
HRP20100600A2 (hr) 2011-03-31
JP5543298B2 (ja) 2014-07-09
HK1071685A1 (en) 2005-07-29
AT501681A1 (de) 2006-10-15
DE102004016947A1 (de) 2004-10-21
HRP20100601A2 (hr) 2011-03-31
IL197578A0 (en) 2011-07-31
DE602004017847D1 (de) 2009-01-02
FR11C0036I1 (fr) 2011-10-14
FR11C0036I2 (fr) 2023-12-29
HRP20050886A2 (en) 2006-11-30
RU2012148593A (ru) 2014-05-20
US20190175527A1 (en) 2019-06-13
CL2004000745A1 (es) 2005-02-11
KR20120101148A (ko) 2012-09-12
CA2521325A1 (en) 2004-10-21
AR043987A1 (es) 2005-08-17
HRP20100601B1 (hr) 2016-12-02
US8324283B2 (en) 2012-12-04
JP5495467B2 (ja) 2014-05-21
FR2854073B1 (fr) 2008-03-14
RU2005134173A (ru) 2006-09-10
EP2316431A1 (en) 2011-05-04
FR2854073A1 (fr) 2004-10-29
BRPI0409250B1 (pt) 2017-07-11
HUE028247T2 (en) 2016-12-28
CY2011013I1 (el) 2014-04-09
HK1155647A1 (en) 2012-05-25
HK1091114A1 (en) 2007-01-12
NO334116B1 (no) 2013-12-16
US20200237690A1 (en) 2020-07-30
US20080311188A1 (en) 2008-12-18
PT1613288E (pt) 2009-02-25
ITMI20040682A1 (it) 2004-07-06
US20060275357A1 (en) 2006-12-07
NZ542622A (en) 2009-01-31
ZA200507394B (en) 2007-03-28
MY141249A (en) 2010-03-31
NO335120B1 (no) 2014-09-22
IL197578A (en) 2015-10-29
PL1613288T3 (pl) 2009-07-31
EP2769713A1 (en) 2014-08-27
RU2010147000A (ru) 2012-08-10
TW200503784A (en) 2005-02-01
KR101367574B1 (ko) 2014-02-25
EP2008650A2 (en) 2008-12-31
US20110105620A1 (en) 2011-05-05
NO20100250L (no) 2006-01-09
AR078782A2 (es) 2011-11-30
RU2009105403A (ru) 2010-08-27
ATE414508T1 (de) 2008-12-15
CN101797241A (zh) 2010-08-11

Similar Documents

Publication Publication Date Title
AU2004228929B2 (en) Organic compounds
AU2008200368B2 (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
AU2011205050B2 (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
HK1155650A (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
HK1155647B (en) Solid oral composition comprising a s1p receptor agonist and a sugar alcohol
HK1091114B (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
IE85095B1 (en) Pharmaceutical composition comprising a sphingosine-1 phosphate receptor agonist

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: GILENYA FINGOLIMOD

Filing date: 20110201

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: GILENYA FINGOLIMOD

Filing date: 20110201

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: GILENYA FINGOLIMOD

Filing date: 20110201

Extension date: 20260201

GD Licence registered

Name of requester: NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED